Connect with us

Health

New Drug Shows Promise in Treating Alzheimer’s Symptoms in Mice

Published

on

A compound derived from common herbs has shown promising results in improving memory and reducing harmful brain protein build-ups in mice, potentially paving the way for new Alzheimer’s treatments.

Breakthrough Study on Memory Enhancement

Researchers from The Scripps Research Institute in the United States have successfully tested a derivative of carnosic acid, a molecule found in rosemary and sage, for its potential in treating Alzheimer’s disease. Their findings, published in the journal Antioxidants, suggest that the compound, called diAcCA, could play a crucial role in combating cognitive decline.

In their study, mice genetically modified to exhibit Alzheimer’s-like symptoms were treated with diAcCA for three months. The results were striking: the mice demonstrated significant improvements in learning and memory, along with an increase in synapses—the vital junctions where neurons communicate. Since synapse loss is strongly linked to cognitive decline, these findings indicate a potential breakthrough in Alzheimer’s research.

Reduction of Alzheimer’s Hallmarks

Beyond cognitive improvements, the treated mice exhibited a reduction in amyloid plaques and tau tangles—two harmful proteins associated with Alzheimer’s. These protein accumulations are key indicators of the disease in humans and contribute to the progressive cognitive deterioration seen in patients.

Professor Stuart Lipton, a senior author of the study, highlighted the dual benefits of diAcCA, stating, “By combating inflammation and oxidative stress, we actually increased the number of synapses in the brain. We also reduced the levels of misfolded or aggregated proteins such as phosphorylated tau and amyloid-β, which are known biomarkers of Alzheimer’s disease.”

An Innovative Approach with Antioxidant Properties

Carnosic acid, the parent molecule of diAcCA, is known for its antioxidant and anti-inflammatory properties. However, it degrades rapidly, making it difficult to use in medical applications. The researchers overcame this limitation by developing diAcCA, a more stable form of the compound that can be taken orally and converted into carnosic acid in the stomach before entering the bloodstream.

According to the study, the amount of the active compound in the blood of treated mice was 20% higher compared to traditional carnosic acid ingestion, suggesting greater efficacy. “We did multiple different tests of memory, and they were all improved with the drug,” Lipton noted. “It didn’t just slow down the decline; it improved virtually back to normal.”

Potential Implications for Alzheimer’s Treatment

Alzheimer’s disease is the most common form of dementia, accounting for 70% of cases. Currently affecting around 7 million people across Europe, this number is expected to double to 14 million by 2030 due to the ageing population.

With promising preclinical results, researchers hope that diAcCA could lead to a viable treatment for Alzheimer’s in humans. The next steps will involve further studies to confirm its effectiveness and safety before progressing to human trials. If successful, this research could mark a significant milestone in the fight against neurodegenerative diseases.

 

Health

Drug-Resistant Superbugs Kill Thousands Across Europe, Threatening Medical Progress

Published

on

Drug-resistant infections are causing more than 35,000 deaths annually across Europe, and health authorities warn the growing threat could undo years of medical progress.

Antimicrobial resistance (AMR) occurs when bacteria, viruses, and other pathogens evolve to survive existing treatments, making infections harder to treat. The resistance also increases risks for patients undergoing procedures such as organ transplants, chemotherapy, and complex surgeries.

The European Centre for Disease Prevention and Control (ECDC) released estimates on Tuesday showing that AMR contributes to tens of thousands of fatalities each year across the European Union, Iceland, Liechtenstein, and Norway. The agency described a “perfect storm” driving the rise in resistance: an ageing population more vulnerable to infections, cross-border spread of drug-resistant pathogens, overuse of antibiotics by doctors and patients, and gaps in infection prevention and control measures.

“We must ensure that no one in Europe is left without an effective treatment option,” said Dr. Diamantis Plachouras, who leads the ECDC’s work on AMR and healthcare-associated infections.

The EU Council set five targets in 2023 to combat AMR, including curbing overall antibiotic use, ensuring at least 65 per cent of antibiotics are first-line treatments, and reducing bloodstream infections from three drug-resistant bacteria. The new report shows that Europe has met only one of these goals.

Bloodstream infections caused by meticillin-resistant Staphylococcus aureus (MRSA) have fallen by 20.4 per cent since 2019, surpassing the target reduction of 15 per cent. However, new bloodstream infections from carbapenem-resistant Klebsiella pneumoniae have risen by over 60 per cent, despite a target reduction of 5 per cent. Highly resistant strains of Escherichia coli (E. coli) have also increased by more than 5 per cent, against a reduction goal of 10 per cent.

Antibiotic use across Europe has risen, including drugs meant only as last-resort treatments. This trend, combined with a shortage of new antibiotics for high-priority pathogens such as carbapenem-resistant gram-negative bacteria (CR-GNB), has left health systems struggling to keep infections under control.

ECDC Director Dr. Pamela Rendi-Wagner said urgent action is needed to curb resistance and support medical advances. “Tackling AMR requires critical innovation,” she said. She called for increased investment in promoting responsible antibiotic use, strengthening infection prevention, and developing new drugs.

Experts warn that without immediate action, Europe could face mounting deaths and rising healthcare costs. AMR is now seen not just as a clinical challenge but as a public health crisis that threatens the safety of routine medical treatments and the ability of hospitals to manage serious infections effectively.

Continue Reading

Health

WHO Warns of Sharp Rise in Mental Health Conditions Among Europe’s Youth

Published

on

A growing number of children and teenagers across Europe are experiencing mental health conditions, with global health officials warning that support systems are failing to keep pace with the surge. A new analysis released by the World Health Organization (WHO) outlines the scale of the challenge and calls for urgent action across the region.

According to the report, one in seven Europeans under the age of 20 are living with a mental health condition — a rise of about one-third over the past 15 years. The findings show clear gender disparities, with girls facing greater vulnerability. Among girls aged 15 to 19, one in four report having a mental health condition, making them the most affected group.

The report also highlights striking differences between countries. Teenagers in the Faroe Islands, Iceland and Denmark ranked among the highest for mental wellbeing, while those in Ukraine, Cyprus and Poland were placed at the lower end of the scale. The data reflects both long-term trends and the impact of recent crises.

Concerns about youth mental health have intensified in recent years, driven by a combination of social isolation, the effects of the COVID-19 pandemic, geopolitical tensions and growing economic pressures. Experts say these factors have created an environment in which young people are increasingly exposed to stress and uncertainty.

Access to professional support remains one of the region’s biggest obstacles. The WHO report notes that about one-quarter of European countries do not have community-based mental health services for young people. In addition, one in five countries lack dedicated mental health policies, leaving many children and teenagers without structured pathways to receive help.

“This report is a wake-up call,” said Dr. João Breda, who works on patient safety and healthcare quality at the WHO. “Every child and young person has the right to mental health support and high-quality care.”

The findings mark the first time the WHO has compiled extensive data on child and youth mental health across its European region, which includes 53 countries in Europe and Central Asia. The report stresses the need for stronger in-person care, noting rising concerns about young people turning to digital tools for emotional support. The document raises alarms about cases in which reliance on artificial intelligence chatbots, including ChatGPT, has led to harmful outcomes.

The WHO is urging governments to strengthen their mental health frameworks by increasing investment, expanding services and updating programmes to better reflect the needs of children and adolescents.

“By acting now, countries can build resilient systems that help the next generations thrive,” Breda said.

Continue Reading

Health

Poliovirus Detected in Hamburg Wastewater, Raising Public Health Alerts

Published

on

Health authorities in Germany have discovered traces of the poliovirus in sewage from Hamburg, highlighting a persistent health threat decades after Europe was declared polio-free. The finding has prompted renewed calls for enhanced disease monitoring and vaccination coverage.

Germany has not reported any confirmed cases of poliomyelitis, a highly contagious disease that primarily affects young children and can invade the nervous system, sometimes causing paralysis. The poliovirus detected in Hamburg’s wastewater is genetically similar to a strain last identified in Afghanistan, one of only two countries where polio remains endemic.

The European Centre for Disease Prevention and Control (ECDC) described the detection as “unusual, but not unexpected.” Germany’s last known locally transmitted polio case occurred in 1990, and the continent was officially declared polio-free in 2002. However, health officials caution that imported cases remain possible, particularly among populations with low vaccination coverage.

The World Health Organization (WHO) emphasized that the discovery underscores the ongoing risk: “Until polio is eradicated everywhere, all countries remain at risk of importation of the virus and potential re-infection.” Poliovirus can appear in sewage when individuals shed the virus in their stool. This does not necessarily indicate illness, as it can also result from people receiving the oral polio vaccine, which contains a weakened live virus.

Last year, similar detections in Germany, Poland, and Spain prompted health authorities to urge countries to strengthen surveillance systems and vaccination campaigns to protect populations from potential outbreaks. Across the European Union, vaccination coverage among one-year-olds ranged from 79 percent in Romania to 99 percent in Hungary and Luxembourg, according to WHO data. Experts note that gaps may persist at the local level, leaving some communities vulnerable to transmission.

Despite the presence of the virus in sewage, the ECDC stressed that the overall risk to the European population remains “very low.” Health authorities are using the findings to monitor trends and reinforce vaccination messaging, particularly in areas where immunization rates fall below recommended levels.

Germany’s recent detection serves as a reminder that polio, although rare in Europe, has not been fully eliminated globally. Public health officials continue to advocate for robust immunization programs, vigilant disease surveillance, and rapid response plans to prevent the virus from spreading should a case arise.

The Hamburg wastewater discovery has renewed focus on the importance of vaccination and monitoring, reinforcing global efforts to ensure that polio remains under control until it is eradicated worldwide.

Continue Reading

Trending